Gilead Sciences Stock Hits Day Low Amid Price Pressure, Closes at $136.49

Gilead Sciences, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 4.98% on March 20, 2026. The stock reached an intraday low of USD 136.49, reflecting a challenging day in the market. Over the past week, Gilead's performance has been down 6.02%, and it has seen a 10.17% decrease over the past month, contrasting with the S&P 500's respective declines of 1.9% and 5.83%. Despite the recent downturn, Gilead has demonstrated strong long-term performance, with a 24.48% increase over the past year, significantly outperforming the S&P 500's 14.9% gain. The company maintains a robust market position, evidenced by a high Return on Capital Employed (ROCE) of 26.79% and a low Debt to EBITDA ratio of 1.56 times, indicating strong financial health. Gilead's market capitalization stands at USD 180,267 million, and it boasts a dividend yield of 2.20%. The stock's performance metrics suggest a solid foundation, even amidst current market fluctuations.